THROMBOSIS

Alembic Pharmaceuticals Ltd received final approval from the US health regulator for generic Dabigatran Etexilate capsules 75 mg and 150 mg to reduce stroke and blood clots in adults with a specific medical condition.

Artificial sweeteners, particularly xylitol, may pose health risks by affecting platelets and blood clotting, leading to cardiovascular events. Caution is advised, with recommendations for natural sweeteners and occasional use of xylitol products fo...

Covishield Side Effects: Controversies surrounding vaccine side-effects persist despite Covid-19 waning. Covishield, developed by AstraZeneca and Oxford University, faces scrutiny in India following reports of rare side effects. Legal battles and de...

Dr. Rajeev Jayadevan, Co-Chairman of the National Indian Medical Association (IMA) Covid Task Force in Kerala, explains that Thrombosis Thrombocytopenia Syndrome (TTS), involving blood clots in rare cases, has been associated with certain vaccines, ...

AstraZeneca acknowledges Covid vaccine risk. Doctors express Covishield concerns. Emphasis on active surveillance. Urgency for investigation, fast track courts, compensation for vaccine injuries.

Akhilesh Yadav slams BJP for risking lives with AstraZeneca's global Covishield withdrawal due to excess supply. How will dangerous vaccine return from recipients? Rare side effect TTS disclosed.

The Serum Institute of India has stopped manufacturing and providing additional doses of the Covishield vaccine due to concerns about its side effects. AstraZeneca has also withdrawn its Vaxzervria vaccine and marketing authorizations within Europe....

The Serum Institute of India (SII) has stated that the safety of vaccines remains "paramount" and that all information about the side effects of its Covishield vaccine against Covid-19 was disclosed in its packaging insert in 2021. The statement com...

SII discloses TTS side-effects. Venugopalan Govindan raises Covishield concerns. Parents plan case against SII. AstraZeneca withdraws VaxAstraZeneca due to mutant variant strains.

Covishield TTS: AstraZeneca has acknowledged the potential TTS side effects from its COVID-19 vaccine Covishield, used widely in India. TTS, Thrombosis with Thrombocytopenia Syndrome, is rare but serious, marked by blood clots and low platelet level...

​In India, where the majority of people were administered Covishield the news of a lawsuit against AstraZeneca in the UK over Covid vaccination has caused concern. Dr Shahid Jameel, virologist and research fellow at Green Templeton College,Universit...

Covishield Vaccine: The recent admission by vaccine maker AstraZeneca in a UK court has sparked discussions about the potential side effect of Thrombosis with Thrombocytopenia Syndrome (TTS) in Covishield, leading many in India to reexamine their va...

Covishield Vaccine Row: Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to p...

Recent revelations by pharmaceutical company AstraZeneca have brought Covid vaccines back into the spotlight, with acknowledgment that its AstraZeneca-Oxford vaccine can, in very rare instances, lead to Thrombosis Thrombocytopenia Syndrome (TTS)," a...

Covishield Covid Vaccine: The Covishield COVID-19 vaccine, developed by AstraZeneca in partnership with the University of Oxford, has been acknowledged for its potential to induce a rare side effect known as Thrombosis with Thrombocytopenia Syndrome...

Every year, World Thrombosis Day is observed on October 13. The International Society on Thrombosis and Haemostasis has set aside this day, to create more awareness about this health condition.

Deion Sanders has been dealing with a health condition for a very long time and has reportedly gone through at least nine surgeries.

After several countries suspended the use of the jab -- including Italy -- the EMA declared that the benefits outweigh the risks and it should remain in use.

Rivaroxaban tablets are indicated for multiple conditions, including reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and treatment of pulmonary embolism (PE).